Impact of telmisartan in modifying vascular risk

Figures & data

Table 1 Biological effects of telmisartan

Angiotensin II type 1 receptors blockage

↓ activation of sympathetic nervous system

↓ endothelin secretion

↑ NO activity

↓ vasoconstriction

↓ vascular and myocardial growth/hypertrophy and fibrosis

↓ apoptosis

Improvement in endothelial function

↓ sodium and water retention

↓ platelet aggregation

Anti-thrombotic effect

↓ systemic inflammation

↓ oxidative stress

Angiotensin II type 2 receptors stimulation

↓ vascular and myocardial growth/hypertrophy and fibrosis

Cell differentiation

Vasodilatation

Other mechanisms

Stimulation of PPAR-γ

↑ insulin sensitivity

↓ glucose and triglycerides levels

↑ adiponectin levels

Abbreviations: NO, nitric oxyde; PPAR-γ, peroxisome proliferator-activator receptor-γ.

Figure 1 Beneficial effects of telmisartan compared with placebo at the end of the TRANSCEND study: blood pressure (difference between both groups: −2.6/−1.1 mmHg),⁴⁹ cardiovascular events (13.0% vs 14.8%, P = 0.048),⁴⁹ and electric left ventricular hypertrophy (9.9% vs 12.8%, P = 0.0017).⁵⁰

Abbreviations: CV, cardiovascular; DBP, diastolic blood pressure; LVH, left ventricular hypertrophy; MI, myocardial infarction; P, placebo; SBP, systolic blood pressure; T, telmisartan.

YusufSTeoKAndersonCfor Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) InvestigatorsEffects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trialLancet20083721174118318757085

 PubMed Web of Science ®Google Scholar

VerdecchiaPSleightPManciaGfor ONTARGET/TRANSCEND InvestigatorsEffects of telmisartan, ramipril, and their combination on left ventricular hypertrophy in individuals at high vascular risk in the ongoing telmisartan alone and in combination with ramipril global end point trial and the telmisartan randomized assessment study in ACE intolerant subjects with cardiovascular diseaseCirculation20091201380138919770395

 PubMed Web of Science ®Google Scholar